Oregon Health And Science University (Ohsu) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Oregon Health and Science University (OHSU) is a public research university and academic health center located in Portland, Oregon. Founded in 1887, OHSU is a leader in neuroscience research, particularly in the areas of Alzheimer's disease, Parkinson's disease, and regenerative medicine.
OHSU houses several major research entities focused on neurodegenerative disease:
- OHSU Brain Institute — coordinates all neuroscience research across the institution
- Jungers Center for Neurosciences Research — fundamental research on neural development, function, and disease
- Parkinson's Disease Research Center — dedicated to understanding PD mechanisms and developing new therapies
- Knight Alzheimer's Disease Research Center — one of the original NIH-funded Alzheimer's Disease Research Centers
- Oregon Center for Aging and Technology (ORCATECH) — developing technology to detect and monitor cognitive decline
OHSU is home to leading researchers including:
- Dr. Jeffrey Kaye (Alzheimer's, aging, technology)
- Dr. Henry Paulsen (Alzheimer's, neuroimaging)
- Dr. Rashawn Johnson (diversity in neuroscience)
- Dr. William M. Brooks (Parkinson's, neuroimaging)
- Development of the Alzheimer's Disease Neuroimaging Initiative (ADNI) protocols
- Pioneering work on biomarkers for early detection of cognitive decline
- Research on lifestyle factors (exercise, diet) in brain health
- Development of assistive technologies for aging populations
- Clinical trials for novel Alzheimer's and Parkinson's therapeutics
- Alzheimer's Disease
- Parkinson's Disease
- Lewy Body Dementia
- Frontotemporal Dementia
- Multiple System Atrophy
- Aging-related cognitive decline
OHSU collaborates with:
- VA Portland Health Care System
- Oregon State University
- Pacific Northwest universities
- National Institute on Aging (NIA)
- Michael J. Fox Foundation for Parkinson's Research
OHSU continues to advance neurodegenerative disease research through the Knight Alzheimer's Disease Research Center and the Parkinson's Institute. New initiatives focus on early detection using fluid biomarkers and advanced neuroimaging techniques. The university is expanding its clinical trial infrastructure to support more Phase II and Phase III studies for novel disease-modifying therapies.
The study of Oregon Health And Science University (Ohsu) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Oregon Health and Science University (OHSU). Official research website.
OHSU houses several state-of-the-art research facilities including the Oregon Stem Cell Center, the Vollum Institute for biomedical research, and the OHSU Knight Cancer Institute. The Portland VA Medical Center provides additional clinical research opportunities.
OHSU offers PhD programs through the School of Medicine, with over 500 graduate students currently enrolled. The neuroscience program is particularly competitive, attracting students from around the world.
OHSU offers several training programs relevant to neurodegeneration:
- Neuroscience Graduate Program: PhD training in cellular and molecular neuroscience
- MD/PhD Program: Combined clinical and research training for physician-scientists
- Postdoctoral Training: Extensive opportunities in neurodegeneration research labs
- Clinical Fellowships: ACGME-accredited fellowships in movement disorders, neurocognitive disorders
OHSU researchers have made significant contributions to neurodegenerative disease research:
- Tau propagation: Discovery of tau oligomers as the most toxic species
- Alpha-synuclein: Early studies on alpha-synuclein aggregation mechanisms
- Neuroimaging: Development of PET tracers for amyloid and tau
- Clinical trials: Leadership in multi-center trials for AD and PD therapeutics
OHSU's strategic priorities include:
- Precision medicine: Genetic and biomarker-guided therapeutic approaches
- Combination therapies: Multi-target treatment strategies
- Early intervention: Identifying and treating preclinical disease stages
- Health equity: Addressing disparities in neurodegeneration care